The Massachusetts Biotechnology Council has released its 2020 Industry Snapshot report, which shows that the Massachusetts biopharma industry raised $2.1 billion in venture capital (VC) investment in the first half of 2020. The IPO market also remained strong, with seven IPOs from Massachusetts biotech companies in the first half of 2020, making up 33% of all […]

Watertown-based, clinical-stage biotech Pandion Therapeutics has announced the initial public offering of 7,500,000 shares of its common stock at a public offering price of $18.00 per share, for gross proceeds of $135 million. The common stock is expected to begin trading on the Nasdaq Global Market on July 17, 2020 under the symbol “PAND.” The offering is expected to close on July […]

Cambridge-based Glympse Bio has closed an oversubscribed $46.7 million Series B financing. The proceeds from the financing will support continued development of Glympse’s novel biosensor platform in fibrotic diseases such as Non-Alcoholic Steatohepatitis (NASH), oncology, and infectious diseases. NASH is a disease that impacts 16 million people in the U.S. and 100 million worldwide. The […]

Waltham-based Adagio Therapeutics has launched with the closing of a $50 million Series A financing to advance its portfolio of coronavirus antibodies as both therapeutics and prophylactics against SARS-CoV-2 as well as future coronavirus outbreaks. Adagio’s antibody candidates have been uniquely engineered and optimized to provide broad protection against SARS-CoV-2, SARSCoV-1, and additional circulating bat […]

Cambridge-based Relay Therapeutics has announced an initial public offering of 20,000,000 shares of its common stock at a price to the public of $20.00 per share. The gross proceeds of the offering are expected to be $400 million. In addition, the underwriters have a 30-day option to purchase up to 3,000,000 additional shares of common […]